MAYO CLINIC ROCHESTER
Biofluid Core
Biofluid Core is a funding opportunity from MAYO CLINIC ROCHESTER, up to 1580507, closing August 31, 2030.
Aug 31, 2030
(1492d left)Overview
ABSTRACT – ALLFTD2: BIOFLUID CORE FTLD encompasses a group of fatal neurodegenerative disorders primarily neuropathologically characterized by the aggregation of tau or TDP-43 proteins. No approved treatment for any FTLD syndrome exists owing, in part, to our incomplete understanding of FTLD pathogenesis and to the…